Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Evotec SE Banner

Evotec SE

EVO Stock Analysis

Page title

Section title

About Evotec SE

Drug Manufacturers - Specialty & Generic
Healthcare

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019...

Evotec SE Key Metrics

Market Cap
$1B
52 Weeks Low
$2.85
52 Weeks High
$12
P/B
0.57x
P/E
-3.36x
P/S
1.45x

Upcoming Events

    EVO Analyst Forecasts

    ‌
    ‌

    EVO Financials

    EVO Income Statement Key Metrics

    • Revenue(TTM)788.44 M
    • Gross Profit(TTM)125.99 M
    • EBITDA(TTM)-81.45 M
    • Net Income(TTM)-170.69 M
    • EPS Diluted(TTM)-0.9712000000000001

    Decode EVO's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    EVO earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of EVO (0.224) is lower than the average of its peers (0.504).

    Net Profit Margin vs Peers

    Net profit margin ratio of EVO (-0.107) is lower than the average of its peers (0.124).

    EVO Return on Equity

    See how efficiently EVO generates profit for it's shareholders.

    -7.49%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of EVO (-0.075) is lower than the average of its peers (0.044).

    Return on Equity Growth

    EVO's Return on Equity has shown poor growth over the past 10 years, increasing by only 5.45%.

    EVO Revenue Growth

    See how EVO has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    EVO's revenue has grown significantly over the past 10 years, increasing by over 24.20%.